At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,406 enrolled
Drug / intervention
Erenumabdrug
Likely dose
Erenumab 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)
In Brief
A Phase 4 clinical trial evaluating Erenumab for Migraine. Completed, enrolled 1,406 participants across 2 sites in 2 countries.
Detailed Summary
To explore the relationship between clinical response to erenumab and genetic biomarkers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesDenmark, Iceland
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartOct 2020
Primary CompletionJan 2023
TodayJul 2026
First PostedFeb 12, 2020
Enrollment StartOct 26, 2020
Primary CompletionJan 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.4 years ago
Interventions
Erenumabdrug
Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).